Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer
US9758495B2 · kind B2 · utility
1Cited by
19References
37Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Mar 13, 2014 |
| Grant date | Sep 12, 2017 |
| Priority date | — |
| Expiry date | Mar 13, 2034 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D417/06
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I).
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.